Bio-Rad Laboratories (BIO) to Release Earnings on Tuesday

Bio-Rad Laboratories (NYSE:BIO) will be releasing its earnings data after the market closes on Tuesday, May 7th. Analysts expect Bio-Rad Laboratories to post earnings of $2.04 per share for the quarter. Investors that are interested in registering for the company’s conference call can do so using this link.

Bio-Rad Laboratories (NYSE:BIO) last released its earnings results on Thursday, February 15th. The medical research company reported $3.10 EPS for the quarter, beating the consensus estimate of $2.93 by $0.17. Bio-Rad Laboratories had a positive return on equity of 3.90% and a negative net margin of 23.86%. The company had revenue of $681.18 million during the quarter, compared to analysts’ expectations of $685.00 million. During the same period last year, the firm earned $3.31 EPS. The business’s revenue for the quarter was down 6.7% on a year-over-year basis. On average, analysts expect Bio-Rad Laboratories to post $10 EPS for the current fiscal year and $11 EPS for the next fiscal year.

Bio-Rad Laboratories Trading Up 0.2 %

Shares of BIO opened at $279.83 on Monday. The stock’s fifty day simple moving average is $318.52 and its 200-day simple moving average is $314.71. The firm has a market capitalization of $7.98 billion, a PE ratio of -13.02 and a beta of 0.94. Bio-Rad Laboratories has a 12-month low of $261.59 and a 12-month high of $468.45. The company has a quick ratio of 4.34, a current ratio of 5.83 and a debt-to-equity ratio of 0.14.

Analyst Ratings Changes

Several brokerages have recently issued reports on BIO. Royal Bank of Canada reduced their target price on shares of Bio-Rad Laboratories from $484.00 to $480.00 and set an “outperform” rating on the stock in a research note on Friday, February 16th. StockNews.com raised shares of Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a research note on Thursday, April 25th. Citigroup cut shares of Bio-Rad Laboratories from a “buy” rating to a “neutral” rating and dropped their target price for the company from $400.00 to $365.00 in a research report on Wednesday, April 3rd. Finally, UBS Group raised their price target on Bio-Rad Laboratories from $395.00 to $420.00 and gave the stock a “buy” rating in a research report on Friday, February 16th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $468.00.

Insider Activity

In other news, EVP Michael Crowley sold 3,000 shares of the company’s stock in a transaction dated Tuesday, February 27th. The stock was sold at an average price of $336.00, for a total value of $1,008,000.00. Following the completion of the sale, the executive vice president now directly owns 6,942 shares of the company’s stock, valued at approximately $2,332,512. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 17.06% of the stock is currently owned by company insiders.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.